Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Ajay K NookaAdam D CohenHans C LeeAshraf Z BadrosAttaya SuvannasankhaNatalie CallanderAl-Ola AbdallahSuzanne TrudelAjai ChariEdward N LibbyMaria ChaudhryMalin HultcrantzK Martin KortümRakesh PopatDouglas SborovShawn HakimEric LewisBoris GorshBharat BhushanAstrid McKeownIra GuptaJoanna OpalinskaPaul G RichardsonSagar LonialPublished in: Cancer (2023)
This final analysis of DREAMM-2 confirms that in patients with triple-class refractory RRMM, single-agent belamaf results in durable and clinically meaningful responses with a manageable safety profile.